MetaCap

Veradermics (MANE) vs Travere Therapeutics (TVTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Veradermics is the larger company by market cap ($5.04 billion vs $4.51 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MANE+216.61%TVTX+48.36%
+331%+150%-32%
Feb 4, 20261 yearNov 20, 2026
MANE+210.60%TVTX+58.20%
+277%+127%-23%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MANE versus TVTX key metrics
MetricMANETVTX
Share price$119.52$47.00
Market cap$5.04B$4.51B
1-day change-3.92%-2.69%
YTD return—+23.00%
1-year return—+35.49%
5-year return—+61.90%
Forward P/E—8.68
EPS (TTM)$-3.89$-1.67
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$490.73M
Revenue growth (YoY)—+110.45%
Net income (latest FY)$-70.00M$-25.55M
Gross margin—97.89%
Operating margin—-12.80%
Net margin—-5.21%
52-week high$156.63$68.73
52-week low$32.00$22.59
Distance from 52-week high-23.69%-31.62%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+56.74%+56.23%
Average volume738.22K1.81M
Shares outstanding42.20M95.99M
Employees51497
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Veradermics

MANE stock →

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.

Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees

About Travere Therapeutics

TVTX stock →

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees

MANE vs TVTX FAQ

Which is bigger, Veradermics or Travere Therapeutics?

Veradermics (MANE) is larger, with a market capitalization of $5.04B compared with $4.51B for Travere Therapeutics (TVTX).

Are Veradermics and Travere Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons